Discover undervalued stocks with Eulerpool.

Subscribe for $2

Opiant Pharmaceuticals Stock OPNT

Price

20.65
Today +/-
+0
Today %
+0 %

Opiant Pharmaceuticals stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Opiant Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Opiant Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Opiant Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Opiant Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Opiant Pharmaceuticals Stock Price History

DateOpiant Pharmaceuticals Price
3/2/202320.65 undefined
2/28/202320.65 undefined

Opiant Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Opiant Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Opiant Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Opiant Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Opiant Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Opiant Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Opiant Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Opiant Pharmaceuticals’s growth potential.

Opiant Pharmaceuticals Revenue, EBIT and net profit per share

DateOpiant Pharmaceuticals RevenueOpiant Pharmaceuticals EBITOpiant Pharmaceuticals Net Income
2026e342.2 M undefined18.76 M undefined1.56 M undefined
2025e193.9 M undefined19.49 M undefined3.67 M undefined
2024e78.18 M undefined-21.32 M undefined8.82 M undefined
2023e38.05 M undefined-31.52 M undefined-20.14 M undefined
2022e9.18 M undefined-42.43 M undefined-44.62 M undefined
202147.79 M undefined5.16 M undefined3.01 M undefined
202029.63 M undefined-2.24 M undefined-1.86 M undefined
201940.52 M undefined10.91 M undefined11.59 M undefined
201813.98 M undefined-21.19 M undefined-21.2 M undefined
201711.76 M undefined1.54 M undefined1.38 M undefined
201618.45 M undefined7.09 M undefined6.58 M undefined
20159.9 M undefined-7.74 M undefined-7.81 M undefined
20141.55 M undefined-6.9 M undefined-7.04 M undefined
20130 undefined-11.3 M undefined-11.48 M undefined
20120 undefined-8.81 M undefined-9.18 M undefined
20110 undefined-12.34 M undefined-12.42 M undefined
20100 undefined-9.44 M undefined-9.44 M undefined
20090 undefined-2.02 M undefined-2.02 M undefined
20080 undefined-10,000 undefined30,000 undefined
20070 undefined-20,000 undefined-20,000 undefined
20060 undefined-30,000 undefined-30,000 undefined
20050 undefined-30,000 undefined-30,000 undefined

Opiant Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
200520062007200820092010201120122013201420152016201720182019202020212022e2023e2024e2025e2026e
0000000001918111340294793878193342
----------800.00100.00-38.8918.18207.69-27.5062.07-80.85322.22105.26147.4477.20
---------3,800.00422.22211.1190.9192.3180.0079.3180.85422.22100.0048.7219.6911.11
000000000000101232233800000
0000-2-9-12-9-11-7-761-2111-13-44-20831
-----350.0033.33-25.0022.22-36.36--185.71-83.33-2,200.00-152.38-109.09-400.00-1,566.67-54.55-140.00-62.50-66.67
0.41.311.311.310.870.671.041.431.751.811.912.244.392.995.344.255.9200000
- - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Opiant Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Opiant Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (k)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (k)
ADDITIONAL PAID-IN CAPITAL (M)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (k)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
20052006200720082009201020112012201320142015201620172018201920202021
                                 
0.0300000.050.020.60.250.431.486.878.1224.6130.9848.2552.87
00000000000.313.7511.74.497.228.9113.33
00000000000000000
00000000000000000
00000000.020.020.030.060.160.940.271.061.942.96
0.0300000.050.020.620.270.461.8510.7820.7629.3739.2659.169.16
00000000000.010001.010.451.08
00000000000000000
00000000000000000
000020302020202020202020101011.6
00000000000000000
0000000000000001.050.18
00000.020.030.020.020.020.020.030.020.020.021.021.511.27
0.030000.020.080.040.640.290.481.8810.820.7829.3940.2860.6170.43
                                 
101010106080130160000000004.9
0.050.050.050.051.3711.0923.1833.743.2544.9856.4858.9466.2291.2897.24100.2108.57
-0.03-0.07-0.08-0.06-2.07-11.51-23.93-34.85-46.33-53.37-61.19-54.6-53.23-74.42-62.83-64.69-61.68
000000000000000-0.03-0.05
00000000000000000
0.03-0.01-0.020-0.64-0.34-0.62-0.99-3.08-8.39-4.714.3412.9916.8634.4135.4846.84
0.010.010.0300.580.410.20.390.550.450.142.213.161.131.322.973.37
00000.0700.060.461.423.133.681.70.711.081.751.190.54
0000000.190.01000.250.251.797.612.542.262.94
0000002203000170000000
00000000000000000
0.010.010.0300.650.410.670.891.973.584.244.165.669.825.616.426.85
00000000000000018.716.07
00000000000000000
00000000.751.415.32.352.312.122.70.2500.67
00000000.751.415.32.352.312.122.70.2518.716.74
0.010.010.0300.650.410.671.643.388.886.596.477.7812.525.8625.1223.59
0.04-00.0100.010.070.050.650.30.491.8810.8120.7729.3840.2760.670.43
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Opiant Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Opiant Pharmaceuticals's financial health and stability.

Assets

Opiant Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Opiant Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Opiant Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Opiant Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (k)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
200520062007200820092010201120122013201420152016null20172018201920202021
0000-2-9-12-9-11-7-7661-2111-13
000000000000000000
000000000000000000
0000000011-4-2-2-714-10-3-4
00001611891111116323
000000000000000001,000
000000000000000000
00000-2-10-1-4055-304-21
000000000000000000
00000000000000000-15
00000000000000000-15
000000000000000000
0000000000000000200
0000030000000517202
00000311041005172192
0000000004200000-10
000000000000000000
0000000000155116617-10
-0.03-0.0300-0.38-2.96-1.1-0.75-1.01-4.24-0.935.560-3.84-0.523.76-2.081.93
000000000000000000

Opiant Pharmaceuticals stock margins

The Opiant Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Opiant Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Opiant Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Opiant Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Opiant Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Opiant Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Opiant Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Opiant Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Opiant Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Opiant Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Opiant Pharmaceuticals Margin History

Opiant Pharmaceuticals Gross marginOpiant Pharmaceuticals Profit marginOpiant Pharmaceuticals EBIT marginOpiant Pharmaceuticals Profit margin
2026e81.03 %5.48 %0.46 %
2025e81.03 %10.05 %1.89 %
2024e81.03 %-27.27 %11.28 %
2023e81.03 %-82.84 %-52.93 %
2022e81.03 %-462.22 %-486.11 %
202181.03 %10.79 %6.3 %
202079.08 %-7.56 %-6.28 %
201980.95 %26.92 %28.6 %
201889.34 %-151.57 %-151.65 %
201788.01 %13.1 %11.73 %
201681.03 %38.43 %35.66 %
201581.03 %-78.18 %-78.89 %
201481.03 %-445.16 %-454.19 %
201381.03 %0 %0 %
201281.03 %0 %0 %
201181.03 %0 %0 %
201081.03 %0 %0 %
200981.03 %0 %0 %
200881.03 %0 %0 %
200781.03 %0 %0 %
200681.03 %0 %0 %
200581.03 %0 %0 %

Opiant Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Opiant Pharmaceuticals earnings per share therefore indicates how much revenue Opiant Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Opiant Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Opiant Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Opiant Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Opiant Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Opiant Pharmaceuticals Revenue, EBIT and net profit per share

DateOpiant Pharmaceuticals Sales per ShareOpiant Pharmaceuticals EBIT per shareOpiant Pharmaceuticals Earnings per Share
2026e57.8 undefined0 undefined0.26 undefined
2025e32.75 undefined0 undefined0.62 undefined
2024e13.21 undefined0 undefined1.49 undefined
2023e6.43 undefined0 undefined-3.4 undefined
2022e1.55 undefined0 undefined-7.54 undefined
20218.07 undefined0.87 undefined0.51 undefined
20206.97 undefined-0.53 undefined-0.44 undefined
20197.59 undefined2.04 undefined2.17 undefined
20184.68 undefined-7.09 undefined-7.09 undefined
20172.68 undefined0.35 undefined0.31 undefined
20168.24 undefined3.17 undefined2.94 undefined
20155.18 undefined-4.05 undefined-4.09 undefined
20140.86 undefined-3.81 undefined-3.89 undefined
20130 undefined-6.46 undefined-6.56 undefined
20120 undefined-6.16 undefined-6.42 undefined
20110 undefined-11.87 undefined-11.94 undefined
20100 undefined-14.09 undefined-14.09 undefined
20090 undefined-2.32 undefined-2.32 undefined
20080 undefined-0.01 undefined0.02 undefined
20070 undefined-0.02 undefined-0.02 undefined
20060 undefined-0.02 undefined-0.02 undefined
20050 undefined-0.07 undefined-0.07 undefined

Opiant Pharmaceuticals business model

Opiant Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development of medications for the treatment of addiction disorders and acute medical needs. The company was founded in 2006 and is headquartered in Santa Monica, California. Since its inception, Opiant Pharmaceuticals Inc. has developed innovative drugs that can help mitigate the effects of addiction disorders and meet the demand for emergency medications. The company follows a clear business model based on the implementation of clinical trials and the commercialization of the resulting medications. One of Opiant Pharmaceuticals Inc.'s core areas is the development of medications that can be used in the context of opioid overdoses. One of the best-known products is Narcan Nasal Spray, an emergency medication that can be used in cases of opioid overdose. The product is fast, easy, and safe to use and has proven to be highly effective in practice. In addition to the development of medications for the treatment of opioid overdoses, Opiant Pharmaceuticals Inc. has also developed medications for the treatment of alcohol dependence. One of the best-known medications is Nalmefene, sold as Selincro in Europe and Canada. The medication is used in combination with behavioral counseling and has proven to be an effective treatment option for patients with alcohol dependence. Another division of Opiant Pharmaceuticals Inc. is the development of medications for acute medical needs. This includes medications such as Fentanyl Nasal Spray, which can be used for the treatment of acute pain. Another medication is the opioid analgesic Oxycodone combined with Naltrexone, which is used for the treatment of moderate to severe pain. In addition, Opiant Pharmaceuticals Inc. also has a wide range of products in the pipeline that are in various stages of development and clinical trials. These include medications for the treatment of methamphetamine and cocaine dependence, as well as for postoperative nausea and vomiting. The company actively invests in research and development and is constantly striving to develop innovative and effective medications that can help minimize the effects of addiction disorders and meet medical needs. Overall, Opiant Pharmaceuticals Inc. has established itself as a leading provider of medications for the treatment of addiction disorders. The company has an impressive track record in drug development and aims to offer effective treatment options to patients around the world. With a strong pipeline of products and a dedicated leadership team, Opiant Pharmaceuticals Inc. is well-positioned to continue growing in the coming years and establish itself as a leading provider of medications for the treatment of addiction disorders. Opiant Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Opiant Pharmaceuticals SWOT Analysis

Strengths

Opiant Pharmaceuticals Inc possesses several strengths that contribute to its success in the pharmaceutical industry.

  • Strong portfolio: Opiant has a robust portfolio of opioid overdose and addiction treatment options, which gives the company a competitive advantage.
  • Established reputation: The company has built a strong reputation for its expertise in developing innovative pharmaceutical solutions.
  • R&D capabilities: Opiant invests significantly in research and development, allowing it to stay at the forefront of medical advancements.
  • Strategic partnerships: Opiant has strategic collaborations with key industry players, enhancing its market presence and expanding its customer base.

Weaknesses

Opiant Pharmaceuticals Inc also faces certain weaknesses that could hinder its growth and performance.

  • Dependency on a few products: The company's revenue heavily relies on a limited number of products, making it vulnerable to market fluctuations.
  • Regulatory challenges: The pharmaceutical industry is subject to stringent regulatory controls, which could result in delays or obstacles for product approvals.
  • Dependency on key personnel: Opiant's success is partially dependent on key personnel, posing a risk in case of talent attrition or succession planning issues.
  • Financial constraints: Limited financial resources may limit the company's ability to finance large-scale research and development projects.

Opportunities

Opiant Pharmaceuticals Inc can leverage the following opportunities to enhance its market position and achieve further growth.

  • Rising demand for opioid addiction treatments: The increasing awareness about opioid addiction presents an opportunity for Opiant to expand its customer base and revenue.
  • Partnerships for international expansion: Collaborations with international pharmaceutical companies can enable Opiant to enter new markets and reach a wider audience.
  • Exploring new therapeutic areas: The company can invest in diversified research to cater to emerging medical needs and tap into new treatment markets.
  • Government initiatives and funding: Support from government bodies and funding for research and development activities can facilitate Opiant's growth and product development.

Threats

Despite its strengths, Opiant Pharmaceuticals Inc faces certain threats that may affect its operations and profitability.

  • Intense competition: The pharmaceutical industry is highly competitive, with numerous companies vying for market share and intellectual property rights.
  • Market volatility: Fluctuations in market conditions, pricing pressures, and changing regulatory landscapes can impact Opiant's ability to generate sustainable revenue.
  • Intellectual property risks: The company's patents and intellectual property may face challenges from competitors or legal infringements.
  • Adverse drug events: Safety concerns or adverse reactions associated with Opiant's products could lead to product recalls or regulatory sanctions.

Opiant Pharmaceuticals Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Opiant Pharmaceuticals Revenue by Segment

Segmente2019
Royalty and licensing revenue37.59 M USD
Grant and contract revenue2.28 M USD
Grant2 M USD
Treatment investment revenue643,955 USD
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Opiant Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Opiant Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Opiant Pharmaceuticals shares outstanding

The number of shares was Opiant Pharmaceuticals in 2024 — This indicates how many shares 5.92 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Opiant Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Opiant Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Opiant Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Opiant Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Opiant Pharmaceuticals stock splits

In Opiant Pharmaceuticals's history, there have been no stock splits.
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Opiant Pharmaceuticals.

Opiant Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2022-1.52 -1.92  (-26.05 %)2022 Q3
6/30/2022-1.39 -2.31  (-65.91 %)2022 Q2
3/31/2022-0.93 -2.43  (-162.5 %)2022 Q1
12/31/2021-0.01 0.11  (1,178.43 %)2021 Q4
9/30/20210.22 0.56  (157.35 %)2021 Q3
6/30/2021-0.29 0.31  (208.54 %)2021 Q2
3/31/2021-0.72 -0.66  (8.87 %)2021 Q1
12/31/20200.07 -0.16  (-313.9 %)2020 Q4
9/30/2020-0.21 0.15  (171.16 %)2020 Q3
6/30/2020-0.25 -0.05  (79.86 %)2020 Q2
1
2

Opiant Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
7.16339 % Western Standard, LLC424,08041,50712/31/2022
3.61480 % Apis Capital Advisors LLC214,00010,00012/31/2022
3.29184 % Morgan Stanley & Co. LLC194,880194,19312/31/2022
3.22246 % The Vanguard Group, Inc.190,7733,61512/31/2022
2.47318 % Renaissance Technologies LLC146,415-30,50012/31/2022
2.31045 % Wells Fargo Advisors136,781-68,30312/31/2022
1.69269 % Dimensional Fund Advisors, L.P.100,209-12,28312/31/2022
1.56475 % Impulse Pharmaceuticals LLC92,63592,63512/16/2022
1.14557 % Gabelli Funds, LLC67,81957,81912/31/2022
1.04579 % IndexIQ Advisors LLC61,91261,91212/31/2022
1
2
3
4
5
...
10

Opiant Pharmaceuticals Executives and Management Board

Dr. Roger Crystal

(45)
Opiant Pharmaceuticals Chief Executive Officer, Director (since 2009)
Compensation 1.48 M

Mr. Phil Skolnick

(75)
Opiant Pharmaceuticals Chief Scientific Officer
Compensation 800,105

Mr. David O'Toole

(63)
Opiant Pharmaceuticals Chief Financial Officer
Compensation 786,669

Mr. Craig Collard

(56)
Opiant Pharmaceuticals Independent Director
Compensation 137,200

Mr. Thomas Thomas

(64)
Opiant Pharmaceuticals Independent Director
Compensation 113,700
1
2

Most common questions regarding Opiant Pharmaceuticals

What values and corporate philosophy does Opiant Pharmaceuticals represent?

Opiant Pharmaceuticals Inc represents a strong commitment to advancing public health through innovative pharmaceutical solutions. The company focuses on developing treatments for life-threatening addictions and drug overdoses. With a dedication to research and development, Opiant strives to improve patient outcomes and address critical medical needs. Through partnerships and collaborations with healthcare professionals, Opiant aims to provide effective and safe interventions for addiction-related disorders. By leveraging its expertise in the field, Opiant Pharmaceuticals Inc remains dedicated to making a positive impact on the lives of individuals struggling with substance abuse.

In which countries and regions is Opiant Pharmaceuticals primarily present?

Opiant Pharmaceuticals Inc is primarily present in the United States.

What significant milestones has the company Opiant Pharmaceuticals achieved?

Opiant Pharmaceuticals Inc has achieved significant milestones throughout its history. One of the major accomplishments includes the development and FDA approval of NARCAN Nasal Spray, a life-saving medication used to reverse opioid overdose. The company has also made strides in the treatment of opioid use disorder with the development of nalmefene, a potential opioid antagonist therapy. Opiant Pharmaceuticals Inc continues to innovate and invest in research and development to address the growing opioid epidemic and improve patient outcomes. Through their dedication and focus, Opiant Pharmaceuticals Inc remains at the forefront of creating effective solutions for opioid-related medical emergencies.

What is the history and background of the company Opiant Pharmaceuticals?

Opiant Pharmaceuticals Inc is a pharmaceutical company specializing in the development of treatments for addiction and overdose. Founded in 2005, Opiant has focused on addressing the opioid crisis through research and innovation. The company has a strong background in opioid antagonist technology, working on advanced formulations of naloxone, a life-saving medication used to reverse opioid overdoses. Opiant Pharmaceuticals Inc has partnered with government agencies, non-profit organizations, and industry leaders to develop and commercialize opioid overdose treatments. With a commitment to saving lives and improving public health, Opiant Pharmaceuticals Inc continues to play a crucial role in combating the opioid epidemic.

Who are the main competitors of Opiant Pharmaceuticals in the market?

The main competitors of Opiant Pharmaceuticals Inc in the market include Emergent BioSolutions Inc, Adapt Pharma Inc, and Kaleo, Inc.

In which industries is Opiant Pharmaceuticals primarily active?

Opiant Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

What is the business model of Opiant Pharmaceuticals?

Opiant Pharmaceuticals Inc. is a biopharmaceutical company that specializes in developing medications for treating addictions and drug overdose emergencies. Their business model revolves around the research, development, and commercialization of innovative therapeutic solutions. Opiant focuses on addressing the opioid crisis through the development of opioid antagonists, rescue medications, and other treatment options. By leveraging their expertise in addiction medicine, Opiant aims to provide effective solutions for patients, healthcare providers, and first responders. With a strong commitment to improving public health, Opiant Pharmaceuticals Inc. works diligently to develop and deliver advanced pharmaceutical products that combat addiction and save lives.

What is the P/E ratio of Opiant Pharmaceuticals 2025?

The Opiant Pharmaceuticals P/E ratio is 33.3.

What is the P/S ratio of Opiant Pharmaceuticals 2025?

The Opiant Pharmaceuticals P/S ratio is 0.63.

What is the Quality Investing of Opiant Pharmaceuticals?

The Quality Investing for Opiant Pharmaceuticals is 2/10.

What is the revenue of Opiant Pharmaceuticals 2025?

The expected Opiant Pharmaceuticals revenue is 193.9 M USD.

How high is the profit of Opiant Pharmaceuticals 2025?

The expected Opiant Pharmaceuticals profit is 3.67 M USD.

What is the business model of Opiant Pharmaceuticals

Opiant Pharmaceuticals Inc. is a leading biotechnology company in the USA specializing in the development and commercialization of drugs for drug abuse and addiction. The company aims to find innovative solutions to challenges arising from drug abuse and addiction through its various divisions. The first division of Opiant Pharmaceuticals focuses on opioid addiction therapy. The company has concentrated on the development of naloxone nasal spray, which is used to treat opioid overdoses. This product is easy to use and has already saved many lives. The second division focuses on the treatment of alcohol addiction. The company has developed a medication called OPNT003, also known as Nalmefene, which reduces cravings and desire for alcohol and helps patients overcome their addiction. It is the only medication of its kind approved in the USA. The third division of Opiant Pharmaceuticals is dedicated to the treatment of bulimia and binge-eating disorders. Here, the company has developed a medication called OPNT002, which reduces appetite and slows down carbohydrate metabolism. The medication has proven effective and will soon be submitted for approval. The fourth and final division of Opiant Pharmaceuticals is the development of medications for the treatment of narcolepsy and other sleep-wake cycle disorders. The company has developed various medications aimed at reducing the symptoms of these disorders and normalizing the sleep-wake cycle. Based on these examples, it is evident that Opiant Pharmaceuticals focuses on the development of medications aimed at treating physical dependencies and disorders. The company's goals are comprehensively covered through its various divisions. Opiant Pharmaceuticals' business model is based on the development and commercialization of innovative solutions for the treatment of addictions and disorders. The company works closely with regulatory authorities and medical institutions to test the products and obtain approval. Once the products are approved, they are marketed and sold by Opiant Pharmaceuticals. To successfully implement the business model, Opiant Pharmaceuticals has built a team of experts who work closely with the various divisions of the company. The company's management has a high level of experience in the pharmaceutical industry and has an extensive network of contacts and partners. In summary, Opiant Pharmaceuticals has an innovative business model aimed at helping people overcome their addictions and disorders. Through the development and commercialization of effective medications, the company continues to be at the forefront of the pharmaceutical industry.

What is the Opiant Pharmaceuticals dividend?

Opiant Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Opiant Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Opiant Pharmaceuticals or the company does not pay out a dividend.

What is the Opiant Pharmaceuticals ISIN?

The ISIN of Opiant Pharmaceuticals is US6837501039.

What is the Opiant Pharmaceuticals WKN?

The WKN of Opiant Pharmaceuticals is A2AFQ6.

What is the Opiant Pharmaceuticals ticker?

The ticker of Opiant Pharmaceuticals is OPNT.

How much dividend does Opiant Pharmaceuticals pay?

Over the past 12 months, Opiant Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Opiant Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Opiant Pharmaceuticals?

The current dividend yield of Opiant Pharmaceuticals is .

When does Opiant Pharmaceuticals pay dividends?

Opiant Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Opiant Pharmaceuticals?

Opiant Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Opiant Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Opiant Pharmaceuticals located?

Opiant Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Opiant Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Opiant Pharmaceuticals from 9/20/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/20/2025.

When did Opiant Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/20/2025.

What was the dividend of Opiant Pharmaceuticals in the year 2024?

In the year 2024, Opiant Pharmaceuticals distributed 0 USD as dividends.

In which currency does Opiant Pharmaceuticals pay out the dividend?

The dividends of Opiant Pharmaceuticals are distributed in USD.

All fundamentals about Opiant Pharmaceuticals

Our stock analysis for Opiant Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Opiant Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.